Competition record
Edwards Lifesciences
Deep profile · 0 linked library matters
Edwards Lifesciences lives on the Sapien transcatheter aortic valve. Medtronic's Evolut is the main alternative, and hospitals that train a structural-heart team on one delivery system keep ordering that valve.
Overview
Edwards is based in Irvine. Sapien valves treat aortic stenosis through a catheter, and Medtronic's Evolut is the other valve used in most of those procedures, with Abbott a smaller supplier.
Surgical tissue valves remain a separate Edwards business for open-chest cases. PASCAL, its mitral repair system, competes with Abbott's MitraClip for a different structural-heart slot in the same labs.
Critical-care products such as Swan-Ganz catheters and the HemoSphere monitor are used in ICUs and cardiac operating rooms, a disposables stream tied to an Edwards monitor. The TAVR contest, though, is won procedure by procedure inside a credentialed heart team.
Competition footprint
Sapien and Evolut split a procedure whose volume follows aging populations and expanding low-risk labels.
Delivery-system training makes a second valve brand a credentialing project, not a spot purchase.
Mitral repair is an Abbott-led adjacency where PASCAL has to earn lab time.
Consumer & business angle
Patients are referred to a structural-heart program, and the program's default valve is the one it stocks.
ICU managers who own HemoSphere monitors keep buying the catheters that talk to it.
What to watch
- Low-risk and asymptomatic aortic-stenosis labels that enlarge the Sapien-versus-Evolut pool.
- Mitral share for PASCAL versus MitraClip, and any second-source valve a heart team agrees to stock.
Markets
transcatheter heart valves · surgical heart valves · critical care monitoring
Also known as: edwards, sapien, pascal
Conduct themes
Linked cases in the library
No linked matters in the current library yet. The narrative above is still a market-power primer — check primary sources for live disputes.